Equities
Health CareMedical Equipment and Services
  • Price (USD)80.65
  • Today's Change-1.66 / -2.02%
  • Shares traded3.47m
  • 1 Year change-8.92%
  • Beta--
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.

  • Revenue in USD (TTM)20.63bn
  • Net income in USD2.09bn
  • Incorporated2022
  • Employees54.00k
  • Location
    GE Healthcare Technologies Inc500 West Monroe StreetCHICAGO 60661United StatesUSA
  • Phone+1 (203) 360-4369
  • Fax+1 (302) 655-5049
  • Websitehttps://www.gehealthcare.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GEHC:NSQ since
announced
Transaction
value
Intelerad Medical Systems IncAnnounced20 Nov 202520 Nov 2025Announced11.53%2.30bn
Icometrix NVAnnounced10 Sep 202510 Sep 2025Announced2.46%--
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Illumina Inc4.34bn850.00m20.42bn8.97k24.457.5028.364.705.465.4627.8417.820.67092.615.41--13.13-10.1517.32-12.1566.6165.3919.57-23.181.72--0.4221---0.66336.04169.505.32----
Waters Corp3.11bn648.81m22.44bn7.60k34.689.6326.357.2210.8710.8752.0239.150.66262.334.38408,636.6013.8418.4117.7623.4658.9658.7120.8922.811.0814.570.37650.000.06674.22-0.68511.61-2.75--
Steris PLC5.83bn708.66m23.93bn17.79k33.933.3427.174.117.197.1859.0973.030.56584.926.12327,662.406.915.047.585.5144.1143.7512.2110.691.7520.990.209437.516.2412.4910.648.4011.528.99
DexCom Inc4.52bn720.70m27.26bn10.30k39.5110.0028.246.041.771.7711.086.990.65193.024.28438,436.9010.408.7916.4111.7560.2064.9715.9614.901.38--0.47850.0011.3422.276.4141.6314.79--
Veeva Systems Inc3.08bn860.33m30.22bn7.29k35.764.2933.589.815.145.1418.4142.840.4234--9.15422,472.4011.8311.3313.5014.3575.6772.6027.9323.96----0.000.0016.2019.9935.8418.8536.56--
Agilent Technologies Inc6.95bn1.30bn36.75bn18.10k28.405.4423.105.294.564.5624.3423.820.56553.294.94383,867.4010.6111.4412.8213.6752.7353.2518.7518.821.5218.300.332220.766.735.411.0912.6327.887.10
GE HealthCare Technologies Inc20.63bn2.09bn37.51bn54.00k18.083.6113.731.824.554.5545.0322.770.58935.934.31381,944.406.156.708.469.2539.9840.4410.4410.491.139.970.48661.854.843.744.570.755813.23--
Resmed Inc5.40bn1.49bn38.90bn10.60k26.406.1523.017.2110.1210.1236.7543.390.69012.345.53509,256.5019.0015.3321.9417.7660.8557.2927.5321.962.32--0.09528.949.8411.7237.2017.64-1.021.69
Edwards Lifesciences Corp5.88bn1.34bn45.32bn15.80k34.224.4430.357.702.282.3310.0117.570.44841.148.35372,392.4010.1914.5211.8116.6178.1979.0122.7225.543.29--0.05540.008.574.5814.555.940.2857--
IDEXX Laboratories Inc4.30bn1.06bn51.39bn11.00k49.20--56.0011.9413.0813.0853.12--------391,245.60--28.96--43.5861.8060.3024.6222.86--37.95----10.429.7219.3312.742.94--
Data as of Feb 06 2026. Currency figures normalised to GE Healthcare Technologies Inc's reporting currency: US Dollar USD

Institutional shareholders

41.20%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 202547.80m10.49%
Dodge & Coxas of 30 Sep 202527.52m6.04%
Capital Research & Management Co. (Global Investors)as of 30 Sep 202524.97m5.48%
BlackRock Fund Advisorsas of 30 Sep 202524.66m5.41%
SSgA Funds Management, Inc.as of 30 Sep 202519.65m4.31%
Geode Capital Management LLCas of 30 Sep 202512.08m2.65%
Harris Associates LPas of 30 Sep 202511.02m2.42%
Hotchkis & Wiley Capital Management LLCas of 30 Sep 20258.43m1.85%
Norges Bank Investment Managementas of 30 Jun 20256.32m1.39%
Invesco Capital Management LLCas of 30 Sep 20255.23m1.15%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.